A surprise breakthrough at the University of Cambridge has introduced a sustainable method for altering complex drug molecules using light rather than toxic chemicals. Published in Nature Synthesis, the study details a light-powered chemical reaction that could accelerate the development of medicines and make pharmaceutical manufacturing more environmentally friendly. The discovery, which the team describes as an anti-Friedel-Crafts reaction, enables precise modification of molecules in the final stages of production—a process known in medicinal chemistry as late-stage functionalization.
The mechanics of anti-Friedel-Crafts alkylation
Traditional Friedel-Crafts reactions, first developed in 1877, typically require harsh experimental conditions, such as strong acids or heavy-metal catalysts. These classical methods are often limited to the early phases of drug manufacturing because they can damage the sensitive structures found in nearly finished medicines. Furthermore, standard Friedel-Crafts chemistry preferentially targets electron-rich aromatic sites.
The new Cambridge approach reverses this selectivity through C-H alkylation of electron-poor aromatics. This method utilizes a visible-light-absorbing electron donor-acceptor (EDA) complex to trigger a self-sustaining radical chain reaction. By forging new carbon-carbon bonds at ambient temperatures, researchers can make targeted changes to a "hit" molecule without dismantling and rebuilding it from scratch.
Key advantages for laboratory operations
- Sustainability: The reaction replaces precious metal catalysts and toxic reagents with an inexpensive LED lamp
- High functional group tolerance: The method can alter specific regions of a molecule without disturbing other sensitive areas
- Time efficiency: Precise adjustments made late in the process can save chemists months of synthetic work
- Scalability: The team successfully demonstrated the reaction on a gram scale and adapted it for continuous-flow systems
Discovery through a failed control experiment
The breakthrough was triggered by an unexpected result during a routine laboratory test. David Vahey, PhD, the first author of the study and a researcher at St John’s College, Cambridge, was testing a photocatalyst when he found that the reaction worked better without it.
"Failure after failure, then we found something we weren't expecting in the mess—a real diamond in the rough," said Vahey. "And it is all thanks to a failed control experiment".
Erwin Reisner, PhD, a professor of energy and sustainability at Cambridge who led the research, emphasized the role of human judgment in the discovery. While artificial intelligence was used to analyze data and predict reactivity, Reisner noted that it still took a human to investigate why a control experiment appeared to "fail".
Machine learning and pharmaceutical applications
To refine the methodology, the researchers collaborated with Trinity College Dublin to develop machine-learning models. These models use Fukui indices to predict where the reaction will occur on new, untested molecules, achieving 93 percent accuracy in experimental tests.
The team also partnered with AstraZeneca to ensure the method could meet the practical demands of industrial pharmaceutical development. During the study, the reaction was used for the late-stage modification of several existing compounds, including the antiretroviral nevirapine and the fungicide boscalid.
By expanding the "chemical space" available to scientists, this tool provides a cleaner and more efficient means of exploring new versions of existing drugs. As the pharmaceutical industry seeks to reduce its environmental footprint, light-powered reactions like this offer a path toward eliminating hazardous waste and reducing energy consumption in the lab.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
